Enhanced ex vivo stimulation of Mycobacterium tuberculosis-specific T cells in human immunodeficiency virus-infected persons via antigen delivery by the Bordetella pertussis adenylate cyclase vector.

Abstract

The genetically detoxified Bordetella pertussis adenylate cyclase is a promising delivery system for immunodominant tuberculosis antigens in gamma interferon release assays. This system has not been evaluated in human immunodeficiency virus (HIV)-infected persons in high tuberculosis prevalence areas. A whole-blood gamma interferon release assay with Mycobacterium tuberculosis antigens (early-secreted antigenic target 6, culture filtrate protein 10, alpha-crystallin 2, and TB10.3) delivered by adenylate cyclase in addition to native tuberculosis antigens (without adenylate cyclase delivery) was evaluated in 119 adults in Khayelitsha Township, Cape Town, South Africa. Results were compared to tuberculin skin test results of 41 HIV-positive and 42 HIV-negative asymptomatic persons, in addition to 36 HIV-positive persons with recently diagnosed smear- or culture-positive pulmonary tuberculosis. Delivery of tuberculosis antigens by adenylate cyclase decreased by 10-fold the amount of antigen required to restimulate T cells. Furthermore, the responses of HIV-positive persons with a low response to native tuberculosis antigens were enhanced when these antigens were delivered by adenylate cyclase. When gamma interferon responses to the tuberculosis antigens (with or without delivery by adenylate cyclase) were combined, a significantly higher number of patients were scored positive than by tuberculin skin testing. Ex vivo responses to tuberculosis antigens delivered by adenylate cyclase are maintained in the context of HIV infection. Our findings suggest that the majority of those in this population are infected with tuberculosis, which is of significant public health importance.

• Authors: Tom G Connell, Muki S Shey, Ronnett Seldon, Molebogeng X Rangaka, Gilles van Cutsem, Marcela Simsova, Zuzana Marcekova, Peter Sebo, Nigel Curtis, Lavanya Diwakar, Graeme A Meintjes, Claude Leclerc, Robert J Wilkinson, Katalin A Wilkinson
• Journal: Clinical and vaccine immunology : CVI (Clin Vaccine Immunol) Vol. 14 Issue 7 Pg. 847-54 (Jul 2007) ISSN: 1556-6811 [Print] United States
• PMID: 17522328 (Publication Type: Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Adenylate Cyclase Toxin
• Antigens, Bacterial
• Immunodominant Epitopes
• Recombinant Fusion Proteins
• Tuberculosis Vaccines
• Interferon-gamma

Topics

• Adenylate Cyclase Toxin (genetics, immunology)
• Adult
• Antigens, Bacterial (genetics, immunology)
• Bordetella pertussis (enzymology, genetics, immunology)
• CD4 Lymphocyte Count
• Dose-Response Relationship, Immunologic
• Drug Delivery Systems
• Female
• HIV Infections (epidemiology, immunology)
• Humans
• Immunodominant Epitopes (administration & dosage, immunology)
• Incidence
• Interferon-gamma (blood)
• Male
• Mycobacterium tuberculosis (immunology)
• Prevalence
• Recombinant Fusion Proteins (genetics, immunology)
• South Africa (epidemiology)
• T-Lymphocytes (immunology, microbiology, virology)
• Tuberculin Test
• Tuberculosis Vaccines (immunology)
• Tuberculosis, Pulmonary (diagnosis, epidemiology, immunology)